Filter
1080
Text search:
medicines
quality
assurance
Featured
134
372
Language
Document type
568
177
138
82
74
20
10
9
1
1
Countries
59
50
48
44
40
30
29
29
26
26
25
25
24
23
21
20
17
15
13
13
11
10
9
9
8
8
7
7
7
7
6
6
5
5
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
562
93
57
54
46
34
18
2
Toolboxes
86
85
84
38
36
32
31
30
23
19
15
13
12
11
10
10
10
7
5
5
4
2
1
1
The second ECDC/EFSA/EMA joint report on the integrated analysis of antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in bacteria from humans and food-producing animals addressed data obtained by the Agencies’ EU-wide surveillance networks for 2013–2015. AMC in both sectors, exp
...
Review over the work and challenges of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) in combatting counterfeiting of medicines in Nigeria.
Malawi Health Sector Strategic Plan 2011 - 2016
recommended
Moving towards equity and quality
Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and
...
“towards quality health and social welfare services”
Global UNIDO Project: Strengthening the local production of essential medicines in least developed and developing countries
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
Second Edition
AIDS Medicines and diagnostics services
July 2015
The occurrence of a high percentage of couterfeit medicines on the global medicines market is often attributed to a lack of effective regulation and a weak enforcement capacity. This review, while f
...
The aim of the Annual Inspection Report is to present findings of public sector health establishments inspected by the OHSC to monitor compliance with the National Core Standards (NCS) during the 2016/2017 financial year in South Africa.
The NCS define fundamentals for
...
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging partic
...
Prices people pay for medicines.
This document is part of the process for improving the quality of care in family planning. Medical eligibility criteria for contraceptive use (MEC), the first edition of which was published in 1996, prsents current World Health Organization (WHO) gu
...
Expanding access to quality health services through task sharing
WHO Model Formulary for Children
recommended
WHO Model Formulary for children based on the Second Model List of Essential Medicines for Children 2009.
In 2007, the World Health Assembly passed a Resolution titled ‘Better Medicines for Chil
...
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and
...
Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men
recommended
This Manual takes into account those lessons to improve and maintain high quality services. It is aligned with updated recommendations on infection prevention and control -- a foundation for all health care services. Voluntary medical male circumcis
...
The Infection Prevention and Control (IPC) Guidelines aim to support healthcare workers improve quality and safety health care. The Guidelines further aim to promote and facilitate the overall goal of IPC by providing evidence-based recommendations
...
The Federal Ministry of Health (FMOH) has been coordinating sector wide reforms that aim to improve equity and quality of health services. It is widely known that; the sector is growing in line the overall growth and transformation
...
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients
...
